RIL’s Q4 results are set to provide crucial insights for investors amidst stock market instability. Key metrics to watch include revenue, growth forecasts, and regulatory impacts.
Jagsonpal Pharmaceuticals is set to initiate its first share buyback plan worth ₹1,100 crore, enhancing investor confidence and reflecting financial strength.